INVO Bioscience Files 8-K for Equity Sale
Ticker: IVF · Form: 8-K · Filed: Sep 18, 2024 · CIK: 1417926
| Field | Detail |
|---|---|
| Company | Invo Bioscience, INC. (IVF) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $137,500, $362,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, equity-securities, 8-k
TL;DR
INVO Bioscience sold equity securities, filing an 8-K on 9/18/24.
AI Summary
On September 12, 2024, INVO Bioscience, Inc. entered into a material definitive agreement related to the unregistered sale of equity securities. The company, incorporated in Nevada with its principal executive offices in Sarasota, Florida, filed this 8-K report on September 18, 2024.
Why It Matters
This filing indicates INVO Bioscience, Inc. has engaged in a transaction involving the sale of equity securities, which could impact its capital structure and shareholder equity.
Risk Assessment
Risk Level: medium — Filings related to unregistered equity sales can introduce uncertainty regarding dilution and future capital structure.
Key Numbers
- 001-39701 — SEC File Number (Identifies the company's filing history with the SEC.)
- 20-4036208 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- INVO Bioscience, Inc. (company) — Registrant
- September 12, 2024 (date) — Date of earliest event reported
- September 18, 2024 (date) — Date of report filing
- Nevada (jurisdiction) — State of incorporation
- Sarasota, Florida (location) — Principal executive offices
FAQ
What type of material definitive agreement was entered into by INVO Bioscience, Inc. on September 12, 2024?
The filing indicates the agreement is related to the unregistered sale of equity securities.
When was this 8-K report filed with the SEC?
The report was filed on September 18, 2024.
In which state is INVO Bioscience, Inc. incorporated?
INVO Bioscience, Inc. is incorporated in Nevada.
What is the address of INVO Bioscience, Inc.'s principal executive offices?
The principal executive offices are located at 5582 Broadcast Court, Sarasota, Florida 34240.
What is the SEC file number for INVO Bioscience, Inc.?
The SEC file number is 001-39701.
Filing Stats: 1,302 words · 5 min read · ~4 pages · Grade level 15.6 · Accepted 2024-09-18 17:21:11
Key Financial Figures
- $0.0001 — ction 12(b) of the Act: Common Stock, $0.0001 par value INVO The Nasdaq Stock Mar
- $137,500 — Company's Series A Preferred Stock for $137,500 pursuant to that certain Securities Pur
- $362,500 — s A Preferred Stock for an aggregate of $362,500 pursuant to the Securities Purchase Agr
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex2-1.htm (EX-2.1) — 42KB
- 0001493152-24-037027.txt ( ) — 266KB
- invo-20240912.xsd (EX-101.SCH) — 3KB
- invo-20240912_lab.xml (EX-101.LAB) — 33KB
- invo-20240912_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 2.1 Fourth Amendment to Agreement and Plan of Merger by and among INVO Bioscience, Inc., INVO Merger Sub, Inc., and NAYA Biosciences, Inc. dated as of September 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 18, 2024 INVO BIOSCIENCE, INC. By: /s/ Steven Shum Steven Shum Chief Executive Officer